AZ divests migraine drug to Grünenthal
AstraZeneca has sold global rights (ex Japan) for its migraine drug Zomig to Grünenthal, as it continues to shed products outside of its area of strategic focus.
Read More
Tag: zolmitriptan
- King’s Doctoral Training Centre to investigate MS symptom management
- Agenda announced for FlyPharma Vienna 2024
- Therapy reprogrammes immune cells to shrink prostate and bladder cancers
- Researchers combine herpes virus with cancer vaccine to treat brain cancer in children
- UK MRC and AstraZeneca partner for translational clinical research
